DENDRID
LOE ApproachingNDAOPHTHALMICSOLUTION/DROPS
Approved
Jun 1963
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 12h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DENDRID is an ophthalmic solution (eye drops) approved by the FDA in 1963 for treating ocular conditions. The exact mechanism of action and indications are not publicly documented in available data, limiting characterization of its therapeutic role. As a legacy small-molecule product, it represents a long-established therapeutic option in eye care.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30); likely a declining or maintenance-mode portfolio asset for Alcon with minimal team expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on DENDRID offers limited career advancement due to zero linked job openings and approaching loss of exclusivity. This is a maintenance-mode product best suited for professionals seeking stability in a legacy portfolio or those gaining foundational experience in mature-market management.
Brand Manager (Ophthalmic)Field Sales Representative
Worked on DENDRID at Alcon? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.